Hydrogen Sulfide Could Reduce Heart Scarring After Attack
A new study in mice suggests a potential way to limit cardiac fibrosis, though clinical application remains years away.
Updated on Oct. 16, 2026 in Heart Disease
A new preclinical study finds that hydrogen sulfide may help reduce cardiac fibrosis following a heart attack. Researchers observed these effects in mouse models by modulating specific protein pathways involved in scarring.
Why it matters
Cardiac fibrosis, or the thickening of heart tissue after an injury, often leads to heart failure. Understanding how to mitigate this process through gasotransmitter pathways could eventually offer new targets for heart disease treatment.
This preclinical study in mouse models demonstrated that hydrogen sulfide treatment reduces the expression of fibrosis-related proteins like COL-I, COL-III, and α-SMA. These findings remain preliminary, as they have not yet been evaluated in human trials.
The details
Hydrogen sulfide works as an endogenous gasotransmitter that influences how heart cells respond to injury. It appears to facilitate the S-sulfhydration of the protein SENP1, which then inhibits the co-localization of TEAD1 and YAP. By disrupting this interaction, the compound prevents the signaling that typically leads to excessive tissue scarring.
Timeline
October 16, 2026: The study was published online.
Health Landscape
This research sits within the ongoing investigation into the cardioprotective effects of gasotransmitters like hydrogen sulfide. It adds to the medical science effort to find pharmacological ways to inhibit cardiac remodeling after myocardial infarction.
While this laboratory study offers insight into cardiac repair, it does not change current care for patients living with heart disease. Any questions regarding treatment for heart health or recovery after a cardiac event should be discussed with a cardiologist.
The takeaway
Cardiac fibrosis remains a complex challenge in the aftermath of a heart attack. Readers are encouraged to continue following standard, physician-approved heart failure management protocols while new treatment strategies move through the research pipeline.
Further reading
For more on the latest research in this area, visit our section on Heart Disease.
Source note: This article includes information reported by Nature.
